The Annual Meeting of the Thai Urological Association (TUA 2024), recently held in Pattaya, Thailand, brought together thousands of urology experts, clinicians, scholars, and leading international medical device companies from across the region, including Dornier MedTech and WIKKON.
As one of Southeast Asia’s most influential urology events, TUA 2024 provided an important platform for showcasing the latest advancements in urological care and shock wave therapy technologies.
At the event, Dornier MedTech and WIKKON presented a range of innovative solutions across their extracorporeal shock wave lithotripsy (ESWL) and therapy (ESWT) portfolio. Featured systems included:
These systems attracted strong interest from attendees for their advanced engineering, user-friendly operation, and refined product design.
In particular, the E300 received significant attention from clinicians and partners across Thailand and Southeast Asia. Since entering the Thai market six years ago, the system has gained growing recognition among healthcare providers for its clinical performance and treatment outcomes, with more than 30 units installed across Thailand to date.
During the event, the Wikkon team, together with its local Thai partner, spoke with several clinical users of the E300 system to better understand treatment experiences and market adoption.
Clinicians shared positive feedback on both WIKKON’s first-generation E100 and its latest E300 erectile dysfunction shock wave therapy systems. They highlighted stable performance, ease of operation, and consistent treatment outcomes — along with high levels of patient satisfaction.
According to WIKKON’s Thai partner, clinics currently using the E300 collectively treat approximately 900 ED patients per month.
Team Photo
Mark Watna, General Manager of WIKKON’s Thai partner company, commented:
“Patients undergoing E300 treatment typically begin to see improvements within one month, with effects that are both meaningful and long-lasting — an important advantage compared to many conventional erectile dysfunction treatment approaches. Through our regular follow-ups, patients consistently express strong satisfaction with the therapeutic outcomes of the E300, which has helped improve both confidence and quality of life.”
WIKKON’s Thai partner also introduced the Wikkon HK.SWT300 during the event for the first time.
The HK.SWT300 is designed primarily for orthopaedic and rehabilitation applications, including conditions such as frozen shoulder and tennis elbow. As a widely recognised non-invasive treatment modality, ESWT continues to gain global acceptance for pain management and musculoskeletal rehabilitation.
Driven by a commitment to innovation and clinical excellence, Dornier MedTech and WIKKON will continue to focus on delivering high-quality medical technologies that support healthcare professionals, medical institutions, and research organisations worldwide.
Looking ahead, both companies remain dedicated to advancing R&D, strengthening manufacturing innovation, and integrating new concepts into their product ecosystem. Through continuous refinement in product design, clinical performance, and operational reliability, Dornier MedTech and WIKKON aims to further improve treatment experiences for clinicians and patients alike.
About WIKKON E300
E300 Erectile Dysfunction Shock Wave Therapy Device
The WIKKON E300 is currently the only domestically manufactured ESWT system for erectile dysfunction in China to hold a domestic manufacturing registration certificate.
Developed using WIKKON’s proprietary core technology, the E300 uses low-intensity extracorporeal shock waves to stimulate angiogenesis and microvascular regeneration, improve penile blood flow and tissue repair, and support the restoration of natural erectile function.
Notably, low-intensity extracorporeal shock wave therapy (Li-ESWT) is increasingly recognised as one of the most promising non-invasive treatment approaches for erectile dysfunction and has been referenced in both American Urological Association (AUA) and European Association of Urology (EAU) guidelines.
The E300 also incorporates WIKKON’s patented innovation technologies, reflecting the company’s continued focus on advancing shock wave medicine through clinically driven innovation.
For business enquiries, partnerships, or product-related questions, please leave us a message and our team will be in touch.
Important Notice: This form is for the above general enquiries only and is not intended for medical emergencies, patient-specific medical advice, product complaints, adverse event reports, device malfunction reports, or other safety-related reports.
For product complaints, adverse events, or device malfunctions, please contact our vigilance team at [email protected] or +86-755-25931606 or contact your local distributor. For medical advice, please consult a qualified healthcare professional. For medical emergencies, contact your local emergency services.
